Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 15/20 | 1.00 |
| ▸ | BCR | P11274 | 14/20 | 1.00 |
| ▸ | SRC | P12931 | 3/20 | 0.70 |
| ▸ | CSF1R | P07333 | 1/20 | 0.70 |
| ▸ | BRAF | P15056 | 1/20 | 0.70 |
| ▸ | FLT3 | P36888 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | KIT | P10721 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22772360 | 0.92 | ABL1 (0.85) | ABL1BCRSRCCSF1RBRAF | |
| SCHEMBL22788769 | 0.86 | ABL1 (1.00) | ABL1BCRSRCCSF1RBRAF | |
| SCHEMBL16755317 | 0.83 | KIT (0.72) | ABL1BCRSRCFGFR1KIT | |
| SCHEMBL22788745 | 0.83 | ABL1 (1.00) | ABL1BCRSRCCSF1RBRAF | |
| SCHEMBL22772364 | 0.82 | ABL1 (1.00) | ABL1BCRSRCCSF1RBRAF | |
| SCHEMBL22772372 | 0.80 | ABL1 (0.65) | ABL1BCRSRCBRAFKCNH2 | |
| SCHEMBL21730532 | 0.79 | ABL1 (0.70) | ABL1BCRSRCFGFR1KDR | |
| SCHEMBL22772390 | 0.79 | ABL1 (1.00) | ABL1BCRSRCCSF1RBRAF | |
| SCHEMBL22772381 | 0.78 | ABL1 (1.00) | ABL1BCRSRCCSF1RBRAF | |
| SCHEMBL22772361 | 0.78 | ABL1 (1.00) | ABL1BCRSRCCSF1RBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11407745-B2 | Indazole derivatives and pharmaceutical composition for preventing, alleviating or treating cancer containing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-08-09 | — | — | US | disclosed |
| US-20200392127-A1 | NOVEL INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-12-17 | — | — | US | disclosed |
| US-20200392127-A1 | NOVEL INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392127-A1 | NOVEL INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER CONTAINING THE SAME | ABL1, DDR1, ABL2 | ABL1 1/4885BCR 10/4885SRC 14/4885 |
| US-11407745-B2 | Indazole derivatives and pharmaceutical composition for preventing, alleviating or treating cancer containing the same | ABL1, DDR1, ABL2 | ABL1 1/4885BCR 9/4885SRC 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.